Sartorius Stedim Biotech (WBO:DIM) Notes Receivable: €0 Mil (As of Mar. 2026)


WBO:DIM Sartorius Stedim Biotech SA WBO:DIM
91 GF Score
Price €179.90
GF Value €205.51
! 5 Warning Signs
View Full Analysis

What is Sartorius Stedim Biotech Notes Receivable?

Sartorius Stedim Biotech WBO:DIM -0.11% 91 Notes Receivable is €0 Mil as of Mar. 2026. GuruFocus rates WBO:DIM with a GF Score™ of 91/100 and a GF Value™ of €205.51. The stock has 5 warning signs investors should review.

Sartorius Stedim Biotech's Notes Receivable for the quarter that ended in Mar. 2026 was €0 Mil.


Sartorius Stedim Biotech Notes Receivable Related Terms


Sartorius Stedim Biotech Notes Receivable Historical Data

* Premium members only.

The historical data trend for Sartorius Stedim Biotech's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sartorius Stedim Biotech Notes Receivable Chart

Sartorius Stedim Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Sartorius Stedim Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
WBO:DIM
91GF Score
Sartorius Stedim Biotech SA WBO:DIM
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sartorius Stedim Biotech Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of €0 Mil mean?
Sartorius Stedim Biotech (WBO:DIM) has a Notes Receivable of €0 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Sartorius Stedim Biotech and its competitors.
Is Sartorius Stedim Biotech's Notes Receivable too high?
Sartorius Stedim Biotech's current Notes Receivable is €0 Mil. Overall, Sartorius Stedim Biotech has a GF Score™ of 91/100, reflecting its overall financial health beyond just this single metric.
How does Sartorius Stedim Biotech's Notes Receivable compare to ISRG and BDX?
Sartorius Stedim Biotech's Notes Receivable of €0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Medical Devices & Instruments company?
A good Notes Receivable depends on the Medical Devices & Instruments industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Sartorius Stedim Biotech and its competitors. Sartorius Stedim Biotech's current Notes Receivable is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius Stedim Biotech stock overvalued right now?
Sartorius Stedim Biotech (WBO:DIM) has a current Notes Receivable of €0 Mil. The stock's GF Value™ is €205.51, compared to a current price of €179.90 — trading 12.5% below its estimated fair value. The current Notes Receivable is €0 Mil. Sartorius Stedim Biotech's overall GF Score™ is 91/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Sartorius Stedim Biotech (WBO:DIM), the current Notes Receivable is €0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sartorius Stedim Biotech (WBO:DIM) Overvalued in 2026?

Based on GuruFocus' analysis, Sartorius Stedim Biotech stock appears to be undervalued. The current stock price of €179.90 is trading 12.5% below its estimated GF Value™ of €205.51.

Key valuation signals for WBO:DIM:

  • Notes Receivable: €0 Mil
  • GF Value™: €205.51 vs. price of €179.90 (12.5% below fair value)
  • GF Score™: 91/100 with 5 warning signs

No single metric tells the full story. See the WBO:DIM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sartorius Stedim Biotech Business Description

Address Otto-Brenner-Strasse 20, Goettingen, DEU, 37079
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. It sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.
91GF Score

Get the complete analysis for WBO:DIM

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€179.90
Price
€205.51
GF Value